This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Aratana Therapeutics Announces Additions To Board Of Directors

KANSAS CITY, Kan., Feb. 5, 2014 /PRNewswire/ --  Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced additions to its Board of Directors.  The Board has appointed two new members; Laura Brege, President and Chief Executive Officer of Nodality, Inc., a privately held life sciences company, and Merilee Raines, former Executive Vice President and Chief Financial Officer of companion animal health company IDEXX Laboratories.  Mses. Brege and Raines will serve on the Audit Committee of the Board, with Ms. Brege as Chairperson.  Aratana also announced the resignation of Board member Ronald Meeusen, Ph.D., Managing Partner of Cultivian Ventures, one of Aratana's early investors.

Jay Lichter, Ph.D., Chairman of the Board of Aratana Therapeutics, stated, "We are pleased to welcome Ms. Brege and Ms. Raines to our Board and to our Audit Committee.  We expect to benefit from Ms. Brege's strong background in finance and extensive executive leadership experience at life sciences and biotechnology companies.  We also look forward to leveraging Ms. Raines' experience as Chief Financial Officer of a public animal health company.  The Board also thanks Dr. Meeusen for his guidance and support for Aratana as an investor and Board member during our transition from private to public ownership."

Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics, stated, "As Aratana continues to evolve, we are pleased to enhance and strengthen our Board with such talented individuals.  We expect to benefit from their leadership and past board experience."

Prior to joining Nodality, Ms. Brege was Executive Vice President, Corporate Affairs of Onyx Pharmaceuticals, Inc., serving previously as Onyx' Chief Operating Officer and Chief Business Officer.  Prior to Onyx, Ms. Brege served as Chief Financial Officer at COR Therapeutics, Inc., a biotechnology company, and Flextronics, Inc., a supply-chain solutions company.  Ms. Brege currently serves on the board of directors of publicly-traded Acadia Pharmaceuticals, Inc., Delcath Systems, Inc. and Pacira Pharmaceuticals, Inc., and served previously on the board of Angiotech Pharmaceuticals, Inc.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,242.93 +110.23 0.61%
S&P 500 2,110.74 +6.24 0.30%
NASDAQ 4,990.2350 +26.7080 0.54%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs